open access

Vol 56, No 2 (2018)
Original paper
Submitted: 2017-12-14
Accepted: 2018-06-02
Published online: 2018-06-07
Get Citation

Immunohistochemical expression of Fascin-1 in colorectal cancer in relation to clinical and pathological parameters

Barbara M. Piskor1, Anna Pryczynicz2, Emilia Lubowicka1, Katarzyna Miniewska3, Justyna Zinczuk2, Konrad Zareba4, Katarzyna Guzinska-Ustymowicz2
DOI: 10.5603/FHC.a2018.0011
·
Pubmed: 29888780
·
Folia Histochem Cytobiol 2018;56(2):106-112.
Affiliations
  1. Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland
  2. Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland
  3. Clinical Research Center, Medical University of Bialystok, Bialystok, Poland
  4. 2nd Department of General and Gastroenterological Surgery, Medical University of Bialystok, Bialystok, Poland

open access

Vol 56, No 2 (2018)
ORIGINAL PAPERS
Submitted: 2017-12-14
Accepted: 2018-06-02
Published online: 2018-06-07

Abstract

   Introduction. Fascins are a group of proteins taking part in the maintenance of a proper structure of the cellular cytoskeleton. Fascin-1 is an actin-bundling protein present in neurons, fibroblasts, endothelial, smooth muscle, dendritic and mesenchymal cells whereas lack of its expression is characteristic of epithelial cells. Fascin-1 overexpression can be observed in neoplastic cells. Therefore, the aim of this study was to assess the expression of Fascin-1 protein in patients with colorectal cancer (CRC) and to analyze associations between Fascin-1 ex­pression and clinical-pathological parameters. Material and methods. The study material included postoperative samples (tumor and unchanged colon tissue) ob­tained from 51 CRC patients. Fascin-1 expression was assessed in the paraffin sections by immunohistochemistry. Results. A statistically significant correlation was found between the histological type of cancer and the expres­sion of Fascin-1 (p = 0.012). Increased expression of Fascin-1 in CRC was more frequent in adenocarcinoma type without the mucosal component with a better prognosis and decreased expression of this protein correlated with infiltration of cancer cells to blood and lymphatic vessels (p = 0.038). Conclusions. Our findings indicate a potential role of Fascin-1 in the pathogenesis of colon cancer; however, further studies will show whether this protein plays a role in the infiltration of colorectal cancer cells.

Abstract

   Introduction. Fascins are a group of proteins taking part in the maintenance of a proper structure of the cellular cytoskeleton. Fascin-1 is an actin-bundling protein present in neurons, fibroblasts, endothelial, smooth muscle, dendritic and mesenchymal cells whereas lack of its expression is characteristic of epithelial cells. Fascin-1 overexpression can be observed in neoplastic cells. Therefore, the aim of this study was to assess the expression of Fascin-1 protein in patients with colorectal cancer (CRC) and to analyze associations between Fascin-1 ex­pression and clinical-pathological parameters. Material and methods. The study material included postoperative samples (tumor and unchanged colon tissue) ob­tained from 51 CRC patients. Fascin-1 expression was assessed in the paraffin sections by immunohistochemistry. Results. A statistically significant correlation was found between the histological type of cancer and the expres­sion of Fascin-1 (p = 0.012). Increased expression of Fascin-1 in CRC was more frequent in adenocarcinoma type without the mucosal component with a better prognosis and decreased expression of this protein correlated with infiltration of cancer cells to blood and lymphatic vessels (p = 0.038). Conclusions. Our findings indicate a potential role of Fascin-1 in the pathogenesis of colon cancer; however, further studies will show whether this protein plays a role in the infiltration of colorectal cancer cells.

Get Citation

Keywords

colorectal cancer; Fascin-1; metastasis; IHC

About this article
Title

Immunohistochemical expression of Fascin-1 in colorectal cancer in relation to clinical and pathological parameters

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 56, No 2 (2018)

Article type

Original paper

Pages

106-112

Published online

2018-06-07

DOI

10.5603/FHC.a2018.0011

Pubmed

29888780

Bibliographic record

Folia Histochem Cytobiol 2018;56(2):106-112.

Keywords

colorectal cancer
Fascin-1
metastasis
IHC

Authors

Barbara M. Piskor
Anna Pryczynicz
Emilia Lubowicka
Katarzyna Miniewska
Justyna Zinczuk
Konrad Zareba
Katarzyna Guzinska-Ustymowicz

References (34)
  1. Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016; 25(1): 16–27.
  2. Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7(3): 105–114.
  3. Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010; 463(7280): 485–492.
  4. Dominguez R, Holmes KC. Actin structure and function. Annu Rev Biophys. 2011; 40: 169–186.
  5. Stricker J, Falzone T, Gardel ML. Mechanics of the F-actin cytoskeleton. J Biomech. 2010; 43(1): 9–14.
  6. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 2005; 37(9): 1787–1804.
  7. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004; 16(5): 590–596.
  8. Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 2010; 42(10): 1614–1617.
  9. Kanda Y, Kawaguchi T, Kuramitsu Y, et al. Fascin regulates chronic inflammation-related human colon carcinogenesis by inhibiting cell anoikis. Proteomics. 2014; 14(9): 1031–1041.
  10. Kulasingam V, Diamandis EP. Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. BMC Med. 2013; 11: 53.
  11. Jawhari AU, Buda A, Jenkins M, et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol. 2003; 162(1): 69–80.
  12. Cheng M, Xue H, Cao W, et al. Receptor for Activated C Kinase 1 (RACK1) Promotes Dishevelled Protein Degradation via Autophagy and Antagonizes Wnt Signaling. J Biol Chem. 2016; 291(24): 12871–12879.
  13. Li A, Dawson JC, Forero-Vargas M, et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 2010; 20(4): 339–345.
  14. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM classification of malignant tumours. Wiley-Blackwell. Oxford 2009.
  15. Guzińska-Ustymowicz K. Tumor budding in colorectal cancer: recent progress in colorectal cancer research. Tetsuichiro Muto E, Mochizuki H, Masaki T.New York: Nova Biomedical Books. Chapter: Aggressive and non-aggressive tumor budding in colorectal cancers. ; 2006: 105–116.
  16. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987; 1(8545): 1303–1306.
  17. Ma Y, Machesky LM. Fascin1 in carcinomas: Its regulation and prognostic value. Int J Cancer. 2015; 137(11): 2534–2544.
  18. Tan VY, Lewis SJ, Adams JC, et al. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013; 11: 52.
  19. Yamashiro S, Yamakita Y, Ono S, et al. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell. 1998; 9(5): 993–1006.
  20. Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007; 67(14): 6844–6853.
  21. Vignjevic D, Kojima Si, Aratyn Y, et al. Role of fascin in filopodial protrusion. J Cell Biol. 2006; 174(6): 863–875.
  22. Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell. 2007; 18(11): 4591–4602.
  23. Schoumacher M, El-Marjou F, Laé M, et al. Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancer. Eur J Cell Biol. 2014; 93(10-12): 388–395.
  24. Li A, Morton JP, Ma Y, et al. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology. 2014; 146(5): 1386–13896.e1.
  25. Kim SuJ, Kim DC, Kim MC, et al. Fascin expression is related to poor survival in gastric cancer. Pathol Int. 2012; 62(12): 777–784.
  26. Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 2005; 11(1): 186–192.
  27. Lin Ck, Su HY, Tsai WC, et al. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis Markers. 2008; 25(1): 17–26.
  28. Lee TK, Poon RTP, Man K, et al. Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett. 2007; 254(2): 308–315.
  29. Puppa G, Maisonneuve P, Sonzogni A, et al. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer. 2007; 96(7): 1118–1126.
  30. Hashimoto Y, Skacel M, Lavery IC, et al. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006; 6: 241.
  31. Oh SY, Kim YB, Suh KW, et al. Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res. 2012; 172(1): 102–108.
  32. Tsai WC, Chao YC, Sheu LF, et al. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers. 2007; 23(3): 153–160.
  33. Ozerhan IH, Ersoz N, Onguru O, et al. Fascin expression in colorectal carcinomas. Clinics (Sao Paulo). 2010; 65(2): 157–164.
  34. Yamamoto H, Kohashi K, Fujita A, et al. Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor. Mod Pathol. 2013; 26(4): 563–571.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl